This is the authors' abstract. We don't add key points for this paper.
Intractable epilepsy was successfully controlled using perampanel, an α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid‐type glutamate receptor antagonist, in a 27‐year‐old woman who presented with a Rett syndrome‐like phenotype and novel 960‐kb deletion involving syntaxin‐binding protein 1 on chromosome 9q34.11. Perampanel may be an effective antiepileptic drug for intractable epilepsy associated with STXBP1 mutations.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yoshida et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: